Global Recombinant Albumin Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Albumin Market Insights, Forecast to 2034
Recombinant albumin is genetically engineered and derived from a rice-based expression system. It is a highly purified and completely animal-, virus-, and bacteria-free product that was developed as an alternative to plasma-derived HSA, to which it is structurally equivalent.
Global Recombinant Albumin market is expected to reach to US$ 80 million in 2024, with a positive growth of %, compared with US$ 75 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Albumin industry is evaluated to reach US$ 121.4 million in 2029. The CAGR will be 7.2% during 2024 to 2029.
The Recombinant Albumin market is primarily driven by the increasing demand for high-quality and safe albumin products in various medical and research applications. Recombinant albumin, produced using biotechnology methods, offers a reliable alternative to traditional plasma-derived albumin, with reduced risk of contamination and consistent quality. The growing prevalence of chronic diseases and the need for albumin in critical care settings, drug formulation, and cell culture contribute to market growth. Moreover, the emphasis on animal-free and sustainable sourcing aligns with the adoption of recombinant albumin. However, challenges include addressing the cost-effectiveness of recombinant production methods and ensuring scalability for large-scale production. Navigating regulatory approvals and market competition, while addressing pricing pressures, are ongoing concerns. The market's success relies on continuous innovation in recombinant protein technology, collaborations between biotechnology companies and pharmaceutical manufacturers, and comprehensive research to demonstrate the safety, efficacy, and cost benefits of recombinant albumin while addressing the evolving challenges associated with protein production, quality assurance, and market acceptance.
Report Covers
This report presents an overview of global Recombinant Albumin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Albumin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia
Segment by Type
OsrHSA
ScrHSA
Cell Culture Media
Medical Supplements
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Albumin plant distribution, commercial date of Recombinant Albumin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Albumin introduction, etc. Recombinant Albumin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant Albumin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Recombinant Albumin market is expected to reach to US$ 80 million in 2024, with a positive growth of %, compared with US$ 75 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Albumin industry is evaluated to reach US$ 121.4 million in 2029. The CAGR will be 7.2% during 2024 to 2029.
The Recombinant Albumin market is primarily driven by the increasing demand for high-quality and safe albumin products in various medical and research applications. Recombinant albumin, produced using biotechnology methods, offers a reliable alternative to traditional plasma-derived albumin, with reduced risk of contamination and consistent quality. The growing prevalence of chronic diseases and the need for albumin in critical care settings, drug formulation, and cell culture contribute to market growth. Moreover, the emphasis on animal-free and sustainable sourcing aligns with the adoption of recombinant albumin. However, challenges include addressing the cost-effectiveness of recombinant production methods and ensuring scalability for large-scale production. Navigating regulatory approvals and market competition, while addressing pricing pressures, are ongoing concerns. The market's success relies on continuous innovation in recombinant protein technology, collaborations between biotechnology companies and pharmaceutical manufacturers, and comprehensive research to demonstrate the safety, efficacy, and cost benefits of recombinant albumin while addressing the evolving challenges associated with protein production, quality assurance, and market acceptance.
Report Covers
This report presents an overview of global Recombinant Albumin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Albumin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia
Segment by Type
OsrHSA
ScrHSA
Segment by Application
Cell Culture Media
Medical Supplements
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Albumin plant distribution, commercial date of Recombinant Albumin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Albumin introduction, etc. Recombinant Albumin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant Albumin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices